5月2日,康宁杰瑞制药-B股价涨超20%。据悉,其KN026关键性II/III期临床试验期中分析达到PFS主要终点,这一进展显著推动了市场对其前景的信心,从而带动股价上涨。此成果或将进一步加速该药物的研发进程。免责声明:本文内容由开放的智能模型自动生成,仅供参考。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.